Skip to main content
JAMA Network logoLink to JAMA Network
. 2023 Feb 28;329(8):687. doi: 10.1001/jama.2023.1481

Updated Disclosures

PMCID: PMC9975908  PMID: 36853259

An author of 2 Letters to the Editor published in JAMA in 20161,2 has provided updated conflict of interest disclosures. The updated disclosures for Dr Ralph Snyderman include serving on the boards of CareDx, Nodality, Press Ganey, Crescendo Biosciences, Targacept Inc, Trevena Inc, Purdue Pharma LLC, and Veritas Collaborative, and the Special Medical Advisory Group of the Department of Veterans Affairs. The disclosure sections of these Letters have been corrected online and a letter of explanation has been published.3

References

  • 1.Snyderman R, Meade C, Drake C. Value of personalized medicine. JAMA. 2016;315(6):613. doi: 10.1001/jama.2015.17136 [DOI] [PubMed] [Google Scholar]
  • 2.Meade C, Drake C, Snyderman R. Health care reform in the United States. JAMA. 2016;316(18):1923-1924. doi: 10.1001/jama.2016.15237 [DOI] [PubMed] [Google Scholar]
  • 3.Snyderman R. Updated conflict of interest disclosures. JAMA. Published February 28, 2023. doi: 10.1001/jama.2023.0160 [DOI] [PubMed] [Google Scholar]

Articles from JAMA are provided here courtesy of American Medical Association

RESOURCES